Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC, Oncolytic virus, Oncolytic Immuno-gene therapy, Anti-PD1 failed, Melanoma, Skin Neoplasms, Nivolumab, RP1 (IT) and nivolumab (IV) in melanoma, RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors, RP1 (IT) and nivolumab (IV) in NMSC
Lead Scientists at UC Cancer
- Gregory Daniels, MD (ucsd)
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
- Bartosz Chmielowski, MD (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 114 research publications
- John Fruehauf, MD (uci)
Recall Faculty, Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences. Authored (or co-authored) 51 research publications
- Katy Tsai, MD (ucsf)
Dr. Katy K. Tsai is a medical oncologist and clinical researcher who specializes in treating advanced melanoma and other non-melanoma skin cancers, such as squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma. Dr. Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown.
- accepting new patients
- Start Date
- Completion Date
- Replimune Inc.
- Phase 2 research study
- Study Type
- Expecting 300 study participants
- Last Updated